Abcentra
PrivateMomentum
Top 10%
of companies Caplight tracks
Company Overview
Abcentra is a clinical-stage biopharmaceutical company developing first-in-class therapeutic antibodies to treat cardiovascular inflammation by blocking oxidized LDL.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abcentra Comparables
Compare Abcentra with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novartis | 78% | |
| DalCor Pharmaceuticals | 71% | |
| Novo Nordisk | 71% | |
Abcentra Funding Rounds
Historical fundraising activity
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Grew 23% QoQ, from 13 to 16 employees.
- Jul 24, 2026
Monthly visitors increased 76% MoM, reaching 4.2K.
Abcentra Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Abcentra's valuation, stock price, and market status.